Methotrexate Withdrawal: Symptoms and Management

Methotrexate does not cause classical drug withdrawal the way opioids or benzodiazepines do, with shaking, sweating, and cravings. Instead, the main risk of stopping methotrexate is a return of the disease it was keeping in check. For people with rheumatoid arthritis, roughly one in five who stop for four weeks will experience a flare, and the numbers climb higher over longer periods. The distinction between “withdrawal symptoms” and disease rebound matters for how you and your doctor plan any break from the drug, whether it is intentional or not.

Why Methotrexate Doesn’t Cause Traditional Withdrawal

Methotrexate works by suppressing parts of the immune system that drive inflammatory conditions like rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis. It is not a drug that changes brain chemistry in ways that create physical dependence. There is no receptor adaptation, no tolerance spiral, and no acute physiological crisis when you stop. The drug itself clears the body fairly quickly, with an elimination half-life of about five to eight hours at the low doses used for autoimmune conditions.¹ Its active metabolites linger in cells somewhat longer, but within a couple of weeks the drug’s direct immunosuppressive effect fades substantially.

What people experience after stopping, then, is not withdrawal in the pharmacological sense. It is the underlying disease reasserting itself once the immunosuppression lifts. For someone whose joints have been quiet for months or years on methotrexate, the return of morning stiffness, swelling, and pain can feel sudden and alarming enough to seem like a withdrawal reaction. Understanding this distinction is more than academic, because it changes how you prepare for and manage a break from the medication.

Disease Flare After Stopping Methotrexate

The most studied consequence of methotrexate discontinuation is the disease flare. In rheumatoid arthritis, flare rates depend heavily on how long the drug is paused. A post-hoc analysis of two randomized trials found that stopping methotrexate for two weeks produced a flare rate of about 11%, close to the roughly 6% seen in people who stayed on the drug. But stretching the pause to four weeks pushed the flare rate to about 21%, a threefold increase over the control group.² The researchers described the four-week flares as transient, meaning most patients recovered once methotrexate was restarted, but the finding underscores how quickly disease activity can rebound.

Over longer horizons the numbers look starker. A study following patients with low disease activity who stopped methotrexate entirely found that about 44% flared within six months, with a median time to flare of roughly 99 days.³ That timeline is important for planning. If you and your rheumatologist decide to attempt discontinuation, the first three to four months are the highest-risk window for a flare, and close monitoring during that period can catch a return of disease before it causes lasting joint damage.

What the Flare Feels Like

A post-discontinuation flare typically involves the same symptoms the person had before starting methotrexate, though the severity and specific pattern vary by condition. In rheumatoid arthritis, you can expect joint stiffness that is worst in the morning, swelling in the small joints of the hands and feet, fatigue, and sometimes low-grade fever. In psoriasis, it tends to mean a return of plaques, itching, and scaling, sometimes in locations that had been clear for months or years.

Some patients also report constitutional symptoms such as weakness and weight loss around the time of discontinuation, though these are less common.⁴ It can be hard to tease apart whether generalized fatigue and malaise are caused by the absence of methotrexate, by the return of systemic inflammation, or by the lingering side effects that prompted stopping the drug in the first place. In practice, the distinction matters less than the management strategy: track symptoms closely, keep your doctor informed, and have a plan for restarting or switching therapy if things worsen.

Psoriasis and the Rebound Problem

Rebound is a particular concern in psoriasis. When methotrexate is stopped abruptly, psoriasis often returns more aggressively than it was before treatment, a phenomenon distinct from a simple relapse. A randomized study compared two tapering approaches to abrupt discontinuation. Among patients who stopped methotrexate cold, about 74% relapsed, compared to roughly 13% in a group that halved their dose before stopping and about 18% in a group that moved to a less frequent dosing schedule before stopping.⁵ The difference was dramatic: tapering, regardless of exactly how it was done, cut rebound risk by roughly four- to sixfold.

This finding carries a practical message. If you have psoriasis and need to stop methotrexate for any reason, working with your dermatologist to step the dose down gradually rather than dropping it all at once can make the transition far smoother. The two tapering methods in the study performed similarly, suggesting that the key factor is avoiding an abrupt withdrawal of immune suppression rather than following one specific taper schedule.

What Improves When You Stop

Not everything gets worse. Methotrexate has real side effects, and stopping the drug allows many of them to resolve. Gastrointestinal complaints like nausea, mouth sores, and stomach upset are among the most common reasons people discontinue methotrexate in the first place, and these typically clear within days to a couple of weeks once the drug is out of the system. The same goes for “methotrexate fog,” a kind of cognitive dullness some people report on dosing days and the day or two after.

Liver-related issues also tend to reverse. A case series examining methotrexate-induced liver injury found that liver enzyme elevations resolved in all patients after the drug was stopped, even in those with comorbidities like diabetes and chronic kidney disease.⁶ If elevated liver enzymes were the reason for discontinuation, blood work typically normalizes over weeks to a couple of months. Hair thinning that started after beginning methotrexate also tends to reverse, though regrowth is slow and may take several months to become visible.

This creates the central tension of methotrexate withdrawal: the side effects you hated may go away, but the disease you needed the drug for comes back. Some patients find the trade-off livable, especially if their disease was mild or in deep remission. Others discover within a few weeks that the disease returning is worse than the side effects were.

Tapering Versus Abrupt Discontinuation

Whether to taper or simply stop depends on the condition and the clinical context. As the psoriasis data showed, tapering makes a substantial difference in skin disease. For rheumatoid arthritis, the evidence is a bit more nuanced. Data from a large Dutch registry of RA patients on biologic therapy found that among those who tapered methotrexate, about 21% relapsed within six months. Among those who fully discontinued, the six-month relapse rate was similar at roughly 21%, climbing to about 24% at twelve months.⁷ Interestingly, disease activity scores in both the taper and discontinuation groups were comparable to those in patients who continued methotrexate at the same dose, which suggests that in RA patients already on a biologic, methotrexate dose reduction or cessation may be tolerable for many.

The key nuance here is that those patients were on TNF inhibitors alongside methotrexate, so they were not left without any immune-modulating therapy. Stopping methotrexate when it is your only disease-modifying drug is a different and riskier proposition than stopping it when a biologic is doing the heavy lifting.

Stopping Methotrexate for Vaccinations

One of the most common reasons for a planned short break from methotrexate is vaccination. Because methotrexate suppresses parts of the immune system, it can blunt the antibody response to vaccines. Research during the COVID-19 pandemic shed useful light on how to handle this. A pair of randomized controlled trials found that pausing methotrexate after vaccination led to significantly higher antibody levels compared to continuing the drug.⁸

The practical takeaway was that skipping methotrexate around the second vaccine dose alone produced a similar antibody boost to skipping it around both doses, without raising the risk of arthritis flares. This “pause once, not twice” approach has since informed broader guidance for other vaccines. Most rheumatologists now suggest holding methotrexate for one to two weeks after an inactivated vaccine like the flu shot or a COVID booster. That window is short enough to keep flare risk low while giving your immune system a better chance at mounting a robust response.

Children and Juvenile Idiopathic Arthritis

In children with juvenile idiopathic arthritis who achieve remission on methotrexate, the question of when to stop the drug comes up frequently. A large randomized trial compared withdrawing methotrexate at six months of remission versus twelve months. The results were strikingly similar: about 57% of children in the six-month group relapsed within two years, compared to about 56% in the twelve-month group.⁹ The median time before relapse was about 21 months in the six-month group and 23 months in the twelve-month group, a difference that was not statistically meaningful.

The relapse rate in both groups may look discouraging at first glance, but there is a hopeful flip side: roughly 43-44% of children in both groups stayed relapse-free through two years. And the finding that waiting an extra six months of treatment did not meaningfully improve the odds suggests that prolonging methotrexate therapy beyond six months of remission does not buy additional protection. For families weighing the side effects and hassle of continued treatment against the risk of relapse, knowing that earlier withdrawal is equally safe can inform the conversation with a pediatric rheumatologist.

Unplanned Gaps and Non-Adherence

Not every interruption in methotrexate is a deliberate medical decision. Missed doses are common. People forget, run out of refills, skip doses because of nausea, or stop temporarily when feeling well and assume they no longer need the drug. The consequences of this kind of unplanned, irregular discontinuation have been documented. In a four-year follow-up study, patients who were non-adherent to methotrexate had significantly higher disease activity scores and worse self-reported health outcomes compared to those who took it consistently.¹⁰ The effect on quality-of-life measures was also significant, suggesting that irregular dosing doesn’t just affect lab numbers but day-to-day functioning.

The finding is worth underscoring because sporadic non-adherence can be insidious. Unlike a planned discontinuation where your doctor is monitoring you closely, missed doses fly under the radar. You may attribute the gradual return of stiffness to aging, weather, or stress rather than recognizing that your drug levels have been inconsistent. If you find yourself frequently skipping doses, that is a conversation worth having at your next appointment. There may be strategies to reduce side effects on dosing days, like switching from oral to injectable methotrexate, adjusting the timing around meals, or adding folic acid supplementation.

When Stopping Is Medically Necessary

Sometimes methotrexate has to stop, not because of disease control but because of the drug’s own adverse effects. In a retrospective study of elderly RA patients, about 27% discontinued methotrexate because of adverse events. The most common were gastrointestinal problems, followed by skin and mucosal issues, liver enzyme elevations, and constitutional symptoms like weakness.⁴ A smaller subset experienced serious complications including interstitial lung disease, severe infections, and gastrointestinal bleeding.

In these cases, management shifts from preventing disease flare to bridging the gap until a replacement therapy can be started. Your rheumatologist may prescribe a short course of low-dose corticosteroids to control inflammation while a new disease-modifying drug takes effect. The timeline matters: most replacement drugs like leflunomide or biologics take weeks to months to reach full effectiveness, so the bridging period requires patience and close communication with your medical team.

Methotrexate and Family Planning

Methotrexate is a known teratogen, meaning it can cause birth defects. Current guidelines advise women to stop methotrexate at least one to three months before attempting conception, and men are generally advised to stop at least three months beforehand as well. This creates a planned withdrawal period where disease management becomes particularly challenging.

The symptoms during this preconception break are the same disease flares described earlier, but the stakes feel different because the usual fallback of restarting methotrexate is not an option during pregnancy. Rheumatologists typically work with patients before conception to identify pregnancy-compatible alternatives like hydroxychloroquine or sulfasalazine for rheumatoid arthritis, or topical therapies and certain biologics for psoriasis. Planning this transition well in advance, ideally months before stopping methotrexate, gives the replacement therapy time to stabilize disease activity before conception is attempted.

Predicting Who Will Flare

Researchers have tried to identify factors that predict who will flare after stopping methotrexate and who will stay in remission. The picture is still incomplete, but several patterns emerge across studies. People who achieved deeper, more sustained remission before discontinuation tend to do better. Those with higher baseline inflammatory markers, shorter remission duration, or more aggressive initial disease are at greater risk. In the registry study of RA patients on biologics, disease activity scores before tapering were a reasonable predictor of outcomes after.⁷

Practically, this means if you have been in rock-solid remission for a year or more with consistently normal lab work, your chances of successfully stopping are better than if you are in fragile remission with occasionally elevated inflammatory markers. But even in the best-case scenario, there is no guarantee, and the studies consistently show that a substantial minority of people who look like excellent candidates for discontinuation will still relapse. This uncertainty is part of the shared decision-making process, and it is why most rheumatologists frame methotrexate cessation as a trial rather than a permanent change: you try, you monitor, and if disease activity returns, you restart.

Restarting After a Break

One piece of reassuring evidence across the literature is that methotrexate generally works again when restarted after a break. Most patients who flare after discontinuation respond to reintroduction of the drug, often at the same dose they were on before. The short-term discontinuation studies described flares as transient, with disease activity returning to baseline once treatment resumed.² This is different from some other medication classes where stopping and restarting can lead to drug resistance or loss of efficacy.

That said, restarting also means re-encountering the side effects you may have been glad to leave behind. The first few weeks back on methotrexate often bring a return of nausea, fatigue on dosing days, and the general sense of being on a medication that your body tolerates rather than enjoys. For most people, these side effects settle back to their previous manageable level within a few cycles. If the side effects were severe enough to make you stop in the first place, the restart conversation is a good time to explore a different route of administration or a different drug entirely.